Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genaissance Pharmaceuticals (GNSC) -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (130)	1/24/2003 12:56:59 PM
From: Jim Oravetz	Respond to of 183

Genaissance Pharmaceuticals In License Pact With BD DOW JONES NEWSWIRES NEW HAVEN, Conn. -- Genaissance Pharmaceuticals Inc. (GNSC) said it will acquire a license to Becton Dickinson & Co's (BDX) proprietary BDProbeTec ET platform and Strand Displacement Amplification technology. Financial terms were not disclosed. The agreement allows Genaissance to offer new tests to better help pharmaceutical partners with validation studies and diagnostic tests to support the marketing of drugs, said Chief Executive Officer Kevin Rakin in a prepared statement. Earlier this week, Genaissance announced a new agreement with Bayer HealthCare LLC's diagnostic unit to help identify pharmacogenomic markers of drug safety and efficacy. Genaisance develops technology that applies population genomics to improve the development, marketing and prescribing of drugs. It also uses population genomics to discover genomic markers that are predictive of which patients will respond effectively to a drug. Becton's BDProbeTec ET is sold worldwide for molecular infectious disease testing. +++ Wow, two deals in a single week. Is this the little engine that could? (PS: Don't own any myself) Jim